The bioconjugation of Herceptin and onaA significantly improved the efficacy of the treatment on both breast cancer cell lines, suggesting a potential advantage of using an immunotoxin treatment for HER-2 positive breast cancers. Here, ERBB2 is linked to breast carcinoma.